NeoGenomics, Inc. (NEO) — Analysis Summary
NeoGenomics, Inc. (NEO) has a market cap of $2.39B with year-over-year revenue growth of +10.1%. Net margin stands at -14.9%. The stock trades at a P/E ratio of -24.1.
Key Takeaways
- Revenue changed +10.1% year-over-year
- Net margin of -14.9%
- P/E ratio of -24.1
Compared to other companies in the SERVICES-TESTING LABORATORIES sector, NEO posted revenue growth of +10.1% and trades at a P/E of -24.1.
NeoGenomics, Inc. (NEO)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -38.9x — earnings do not cover interest payments
Operating margin at -14.2% — material operating losses
The latest filing shows negative free cash flow.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Sector
SERVICES-TESTING LABORATORIES
Employees
2,500
Headquarters
FORT MYERS, FL
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.